Related Experiment Video

Updated: Aug 8, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting

Aurélie Telliez1, Christophe Furman, Nicole Pommery

  • 1Institut de Chimie Pharmaceutique Albert Lespagnol, EA 2692, 3 rue du Professeur Laguesse, BP 83, F-59006 Lille, France.

Anti-Cancer Agents in Medicinal Chemistry
|May 23, 2006
PubMed

Insights

Cyclooxygenase-2 (COX-2) promotes cancer by synthesizing prostaglandins, driving tumor growth, and suppressing immunity. This review details COX-2

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) is an inducible enzyme that converts arachidonic acid into prostaglandins (PGs) and thromboxanes (TXs).
  • Overexpression of COX-2 is implicated in numerous cancers, contributing to tumor progression.
  • COX-2 facilitates cancer development by enhancing cell proliferation, angiogenesis, invasion, and immune evasion, while inhibiting apoptosis.

Purpose of the Study:

  • To elucidate the mechanisms by which COX-2 metabolites promote cancer development.
  • To describe the signaling pathways regulating COX-2 expression.
  • To review chemical agents designed to counteract COX-2's pro-cancer effects.

Main Methods:

  • Literature review focusing on COX-2's role in cancer.
  • Analysis of signaling pathways involved in COX-2 expression and activity.
  • Overview of therapeutic strategies targeting COX-2.

Main Results:

  • COX-2 metabolites stimulate PG receptors, leading to increased cellular proliferation, angiogenesis, invasion, and immune suppression.
  • Multiple signaling pathways (e.g., Kinases, Rho, cGMP, Wnt) and transcription factors (e.g., AP1, NFAT, NF-kappaB) regulate COX-2 expression.
  • Development of chemical inhibitors targeting COX-2 activity and expression pathways.

Conclusions:

  • COX-2 is a critical mediator of cancer progression through prostaglandin synthesis.
  • Understanding COX-2 signaling pathways is essential for developing targeted cancer therapies.
  • Chemical interventions targeting COX-2 offer a promising strategy to inhibit cancer development.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...